These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 9224313

  • 21. [M-VAC chemotherapy for advanced urothelial cancer--side effects and their management].
    Noguchi S, Kubota Y, Shuin T, Masuda M, Misaki H, Yao M, Kondoh K, Sakuramoto T, Hosaka M.
    Hinyokika Kiyo; 1994 Aug; 40(8):677-82. PubMed ID: 7942364
    [Abstract] [Full Text] [Related]

  • 22. Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen.
    Kouno T, Ando M, Yonemori K, Matsumoto K, Shimizu C, Katsumata N, Komiyama M, Okajima E, Matsuoka N, Fujimoto H, Fujiwara Y.
    Eur Urol; 2007 Oct; 52(4):1115-22. PubMed ID: 17433855
    [Abstract] [Full Text] [Related]

  • 23. [M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy in advanced renal pelvic and ureteral carcinoma].
    Igawa M, Ueki T, Ueda M, Okada K, Usui T, Ohnishi Y, Kume T, Masu C, Ishino T, Nakatsu H.
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2577-82. PubMed ID: 2673046
    [Abstract] [Full Text] [Related]

  • 24. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium.
    Dreicer R, Manola J, Roth BJ, See WA, Kuross S, Edelman MJ, Hudes GR, Wilding G.
    Cancer; 2004 Apr 15; 100(8):1639-45. PubMed ID: 15073851
    [Abstract] [Full Text] [Related]

  • 25. Role of paclitaxel, ifosfamide, and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Shin DM, Glisson BS, Khuri FR, Hong WK, Lippman SM.
    Semin Oncol; 1998 Apr 15; 25(2 Suppl 4):40-4; discussion 45-8. PubMed ID: 9578061
    [Abstract] [Full Text] [Related]

  • 26. [Sequential combination chemotherapy consisting of vincristine, peplomycin, methotrexate, cis-diamminedichloroplatinum (II), cytosine arabinoside and 5-fluorouracil, for advanced urothelial cancer].
    Yamauchi T, Hida S, Ooishi K, Okada K, Yoshida O.
    Hinyokika Kiyo; 1985 Jul 15; 31(7):1093-104. PubMed ID: 2414981
    [Abstract] [Full Text] [Related]

  • 27. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
    Musolino A, Perrone MA, Michiara M, Delnevo D, Franciosi V, Di Blasio B, Ceci G, Camisa R, Ardizzoni A, Cocconi G.
    Cancer; 2005 May 15; 103(10):2109-17. PubMed ID: 15803492
    [Abstract] [Full Text] [Related]

  • 28. Results of adjuvant chemotherapy for invasive urothelial cancer with lymph-node metastasis.
    Kobayashi H, Obata K.
    Cancer Chemother Pharmacol; 1994 May 15; 35 Suppl():S14-7. PubMed ID: 7994781
    [Abstract] [Full Text] [Related]

  • 29. CMV chemotherapy for advanced transitional cell carcinoma.
    Jeffery GM, Mead GM.
    Br J Cancer; 1992 Sep 15; 66(3):542-6. PubMed ID: 1520591
    [Abstract] [Full Text] [Related]

  • 30. Impact of recombinant human granulocyte colony stimulating factor on dose intensity and toxicity of three cycles of methotrexate, vinblastine, doxorubicin and cisplatin in patients with previously untreated urothelial bladder carcinoma.
    Viens P, Gravis G, Bladou F, Lechevallier E, Baume D, Camerlo J, Cowen D, Coulange C, Serment G, Resbeut M, Maraninchi D.
    Eur Cytokine Netw; 1996 Sep 15; 7(3):395-9. PubMed ID: 8954183
    [Abstract] [Full Text] [Related]

  • 31. Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study.
    Tsavaris N, Kosmas C, Skopelitis H, Dimitrakopoulos A, Kopterides P, Bougas D, Stravodimos K, Mitropoulos D, Alamanis C, Giannopoulos A.
    J Chemother; 2005 Aug 15; 17(4):441-8. PubMed ID: 16167525
    [Abstract] [Full Text] [Related]

  • 32. [Preliminary results of a phase II randomized controlled trial comparing M-VAC and M-CAVI in patients with bladder cancer (T2-4 N0-1 M0)].
    Bellmunt Molins J, Ribas A, Albanell J, Lorente Garín JA, de Torres Mateos JA, Morote Robles J, López Palacios MA, Banús Gassol JM, Casado Cobo S, Eres N, Solé Calvo LA.
    Arch Esp Urol; 1996 Jun 15; 49(5):465-72. PubMed ID: 8766083
    [Abstract] [Full Text] [Related]

  • 33. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for poor prognosis patients with urothelial tumors and effect of dose intensity.
    Hibi H, Okamura K, Takashi M, Shimoji T, Miyake K.
    Hinyokika Kiyo; 1997 Feb 15; 43(2):89-96. PubMed ID: 9086342
    [Abstract] [Full Text] [Related]

  • 34. Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95).
    Lehmann J, Retz M, Wiemers C, Beck J, Thüroff J, Weining C, Albers P, Frohneberg D, Becker T, Funke PJ, Walz P, Langbein S, Reiher F, Schiller M, Miller K, Roth S, Kälble T, Sternberg D, Wellek S, Stöckle M, AUO-AB 05/95.
    J Clin Oncol; 2005 Aug 01; 23(22):4963-74. PubMed ID: 15939920
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
    Segal R, Winquist E, Lukka H, Chin JL, Brundage M, Markman BR, Cancer Care Ontario Practice Guidelines Initiative Genitourinary Cancer Disease Site Group.
    Can J Urol; 2002 Oct 01; 9(5):1625-33. PubMed ID: 12431323
    [Abstract] [Full Text] [Related]

  • 37. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH, Cheng AL, Hsu C, Yang CH, Lu YS, Lin CC, Bu CF, Yeh KH.
    Anticancer Res; 2002 Oct 01; 22(6B):3621-7. PubMed ID: 12552966
    [Abstract] [Full Text] [Related]

  • 38. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
    Loehrer PJ, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R, Sarosdy MF, Lowe BA.
    J Clin Oncol; 1992 Jul 01; 10(7):1066-73. PubMed ID: 1607913
    [Abstract] [Full Text] [Related]

  • 39. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.
    Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, Morse MJ, Sogani PC, Vaughan ED, Bander N.
    Cancer; 1989 Dec 15; 64(12):2448-58. PubMed ID: 2819654
    [Abstract] [Full Text] [Related]

  • 40. [Two cases of urothelial cancer responsive to high-dose-intensity methotrexate vinblastine doxorubicin and cisplatin (M-VAC) therapy].
    Fukuda H, Mitsumori K, Minagawa S, Kumazawa T, Tadachi K, Iinuma M, Satoh S, Satoh K, Habuchi T, Kato T.
    Hinyokika Kiyo; 2005 Feb 15; 51(2):113-6. PubMed ID: 15773365
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.